Hormone replacement therapy
Does Hormone Therapy Raise Breast Cancer Risk?
Whether menopausal hormone therapy raises breast cancer risk depends on the regimen. In the largest randomized trials, estrogen with a progestin was linked to a higher rate and estrogen alone to a lower one, and FDA labeling was recently revised.
Short answer
It depends on the regimen. In the Women’s Health Initiative randomized trials, estrogen plus a progestin was associated with a higher breast cancer rate, while estrogen alone was associated with a lower one (Chlebowski et al., 2020). In February 2026 the FDA approved label changes that removed the boxed warnings for breast cancer, cardiovascular disease and probable dementia from menopausal hormone products, and kept the one for endometrial cancer with unopposed estrogen (U.S. Food and Drug Administration, 2026). Your own risk is a physician-guided decision.
What this means
Breast cancer is one of the most common worries women raise about menopausal hormone therapy, and the answer has changed shape over time. Early reports from the Women’s Health Initiative (WHI) in the early 2000s led many women and physicians to stop hormone therapy. Longer follow-up showed a more divided picture: the result depended on whether a progestin was part of the regimen, and on whether the woman still had a uterus (Chlebowski et al., 2020).
A label change is not a clean bill of health. A boxed warning is the most prominent safety statement on a medication label. The FDA’s announcement addresses those warnings, and the full current label for the specific product still governs prescribing.
Candidacy
Hormone therapy is generally considered for women with bothersome menopausal symptoms, and the FDA’s announcement says that women who start within 10 years of menopause onset, generally before age 60, had lower all-cause mortality and fewer fractures in randomized studies (U.S. Food and Drug Administration, 2026). That statement is the FDA’s, and it concerns population averages, not any one patient. A personal history of breast cancer, a strong family history, unexplained vaginal bleeding, or a history of blood clots or stroke are reasons for extra caution and often for input from an oncologist or other specialist. Candidacy is decided after an evaluation.
Clinical evaluation
A physician evaluation before starting should cover:
- Breast health history. Personal and family history of breast or ovarian cancer, prior biopsies, breast density, and the date and result of your last mammogram.
- Uterus status. Whether you have a uterus determines whether a progestin is needed alongside estrogen to protect the uterine lining.
- Timing. Your age and how long ago menopause began.
- Cardiovascular and clot risk. Blood pressure, lipids, smoking, prior clots, and migraine with aura.
- Symptoms and goals. Which symptoms matter most, and what you want from therapy.
Available options
Options differ by the hormone, the dose and the route. Estrogen alone is used for women without a uterus, and estrogen with a progestin for women who have one. Delivery can be a pill, a patch, a gel, or a vaginal product for local symptoms. Non-hormonal options exist for hot flashes, and your physician can discuss them if hormones are not a good fit. PrimeCell offers hormone replacement therapy for women and men, and which regimen fits is discussed after an evaluation and labs when indicated.
Benefits, limitations and risks
Hormone therapy can reduce hot flashes and night sweats and support bone density for many women, and the FDA cites fewer fractures with early initiation (U.S. Food and Drug Administration, 2026). The risks include breast cancer risk that may rise with combined estrogen and progestin, blood clots and stroke risk that vary by route and dose, and, for estrogen without a progestin in a woman with a uterus, endometrial cancer. That last risk is why the endometrial boxed warning remains.
Regular screening mammograms stay part of routine care for women on hormone therapy, because breast density and risk can change over time. Your physician will recommend a schedule for your age and history.
What the evidence shows
What it establishes: The 2020 JAMA analysis followed 27,347 postmenopausal women for a median of more than 20 years. Among 16,608 women with a uterus, estrogen plus progestin was associated with more breast cancers than placebo (584 vs. 447 cases; hazard ratio 1.28; 95% CI 1.13 to 1.45). Among 10,739 women who had a hysterectomy, estrogen alone was associated with fewer (238 vs. 296 cases; hazard ratio 0.78; 95% CI 0.65 to 0.93), and fewer breast cancer deaths (30 vs. 46; hazard ratio 0.60; 95% CI 0.37 to 0.97) (Chlebowski et al., 2020). The researchers reported that the difference persisted after the therapy stopped (American Association for Cancer Research, 2019).
What it does not establish: that every regimen behaves the same way. The trials tested one oral estrogen and one progestin, so the findings do not directly cover patches, gels, micronized progesterone or other products. For combined therapy, the difference in breast cancer deaths was not statistically significant (71 vs. 53 deaths; hazard ratio 1.35; 95% CI 0.94 to 1.95) (Chlebowski et al., 2020). The women in these trials enrolled in the 1990s, and results for women who start early for symptoms may differ.
Recovery and next steps
If you are weighing hormone therapy, bring your last mammogram date, your family history and a list of your medications to the evaluation, and ask which regimen is proposed and why. If you start, your physician will schedule a follow-up to check symptoms and side effects and will review the plan at least once a year. Individual results vary.
Frequently asked questions
Did the FDA say hormone therapy no longer raises breast cancer risk?
No. The FDA approved label changes that removed the boxed warning for breast cancer, among others. That is a change in how the label presents the information, and it does not mean risk is absent. The full label for your product still applies.
Is estrogen alone safer for the breast than estrogen with a progestin?
In the WHI trials, estrogen alone was associated with fewer breast cancers and estrogen plus progestin with more. Estrogen alone is only used in women without a uterus, so the comparison does not apply to everyone.
Do patches or micronized progesterone carry the same risk?
The WHI trials did not test them, so they cannot answer that question directly. Ask your physician what is known about the specific product proposed.
Do I still need mammograms on hormone therapy?
Yes. Routine screening continues, on a schedule your physician recommends for your age and history.
References
- U.S. Food and Drug Administration. (2026, February 12). FDA approves labeling changes for menopausal hormone therapy products. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
- Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., Manson, J. E., Stefanick, M. L., Pan, K., et al. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women’s Health Initiative randomized clinical trials. JAMA. https://ohiostate.elsevierpure.com/en/publications/association-of-menopausal-hormone-therapy-with-breast-cancer-inci/
- American Association for Cancer Research. (2019). Long-term follow-up shows estrogen alone and estrogen plus progestin have opposite effects on breast cancer incidence in postmenopausal women. https://www.aacr.org/about-the-aacr/newsroom/news-releases/long-term-follow-up-shows-estrogen-alone-and-estrogen-plus-progestin-have-opposite-effects-on-breast-cancer-incidence-in-postmenopausal-women/
Medically reviewed by Kenny Chantasi, DO, on October 6, 2026. General education only; not a substitute for individual medical advice. Individual results vary. Treatment options are discussed after a medical evaluation. In an emergency, call 911.